Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 10/2023

13-03-2023 | Melanoma | Research

The evaluation of tumor microenvironment infiltration and the identification of angiogenesis-related subgroups in skin cutaneous melanoma

Authors: Junpeng Li, Hangjun Ren, Hongyu Huai, Junliang Li, Pan Xie, Xiaolu Li

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2023

Login to get access

Abstract

Background

There are limited studies on the association between angiogenesis-related genes (ARGs) and the predictive risk of melanoma, even though angiogenic factors, which are essential for tumor growth and metastasis, might be secreted by angiogenesis-related protein in skin cutaneous melanoma (SKCM). To forecast patient outcomes, this study attempts to develop a predictive risk signature linked to angiogenesis in cutaneous melanoma.

Methods

In 650 patients with SKCM, the expression and mutation of ARGs were examined, and this information was related to the clinical prognosis. SKCM patients were split into two groups based on how well they performed on the ARG. The link between ARGs, risk genes, and immunological microenvironment was examined using a range of algorithmic analysis techniques. Based on these five risk genes, an angiogenesis risk signature was created. We developed a nomogram and examined the sensitivity of antineoplastic medications to help the proposed risk model's clinical applicability.

Results

The risk model developed by ARGs revealed that the prognosis for the two groups was significantly different. The predictive risk score was negatively connected with memory B cells, activated memory CD4 + T cells, M1 macrophages, and CD8 + T cells, and favorably correlated with dendritic cells, mast cells, and neutrophils.

Conclusions

Our findings offer fresh perspectives on prognostic evaluation and imply that ARG modulation is implicated in SKCM. Potential medications for the treatment of individuals with various SKCM subtypes were predicted by drug sensitivity analysis.
Appendix
Available only for authorised users
Literature
go back to reference Emmett MS, Dewing D, Pritchard-Jones RO (2011a) Angiogenesis and melanoma - from basic science to clinical trials. Am J Cancer Res 1:852–868PubMedPubMedCentral Emmett MS, Dewing D, Pritchard-Jones RO (2011a) Angiogenesis and melanoma - from basic science to clinical trials. Am J Cancer Res 1:852–868PubMedPubMedCentral
go back to reference Rastrelli M, Tropea S, Rossi CR et al (2014) Melanoma epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo 28:1005–1011PubMed Rastrelli M, Tropea S, Rossi CR et al (2014) Melanoma epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo 28:1005–1011PubMed
go back to reference Warren BA, Shubik P (1966) The growth of the blood supply to melanoma transplants in the hamster cheek pouch. Lab Invest 15:464–478PubMed Warren BA, Shubik P (1966) The growth of the blood supply to melanoma transplants in the hamster cheek pouch. Lab Invest 15:464–478PubMed
Metadata
Title
The evaluation of tumor microenvironment infiltration and the identification of angiogenesis-related subgroups in skin cutaneous melanoma
Authors
Junpeng Li
Hangjun Ren
Hongyu Huai
Junliang Li
Pan Xie
Xiaolu Li
Publication date
13-03-2023
Publisher
Springer Berlin Heidelberg
Keywords
Melanoma
Melanoma
Published in
Journal of Cancer Research and Clinical Oncology / Issue 10/2023
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-023-04680-8

Other articles of this Issue 10/2023

Journal of Cancer Research and Clinical Oncology 10/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine